ClinicalTrials.gg
Active, not recruitingNCT03796962X-TOLEUpdated Nov 5, 2026Results posted

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

A Phase 2 interventional study of XEN1101 in Focal Epilepsy, sponsored by Xenon Pharmaceuticals Inc.. Active, not recruiting at 95 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Xenon Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Updated Nov 5, 2026Study completion movedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.

Enrollment
17th of 86
325 · median 100
Started
2019
with 1 other
Phase 2
23 of 102
4 open now
Primary completion
2021-09
later than 0 of 22 live
Registered
71st of 102
by date

Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 17th largest by enrollment of the 86 interventional ones that give a count, is one of 2 that started in 2019, is one of 23 in phase 2, reaches primary completion later than 0 of the 22 other live ones, and was the 71st registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Epilepsies, Partial with a site in United States, or all of them as a file.
02

Study summary

The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).

Read the detailed description

The XEN1101 Phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled, multicenter study with an optional open-label extension (OLE) to evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive treatment in adult patients aged 18 to 75 years diagnosed with focal epilepsy. Approximately 300 patients will be randomized in a blinded manner to one of three active treatment groups or placebo in a 2:1:1:2 fashion (XEN1101 25 mg : 20 mg : 10 mg : Placebo). After screening, patients will have 8 weeks of baseline to assess frequency of seizures, followed by 8 weeks of treatment and a 6-week post treatment follow-up period. In order to be included in the study, patients must already be treated with a stable dose of 1 to 3 allowable current anti-epileptic drugs for at least one month prior to screening, during baseline, and throughout the double-blind portion (DBP) of the study. During the treatment period, patients will be given XEN1101 or placebo once daily in the evening. An OLE will be available to eligible patients who complete the DBP. All patients will receive a 20 mg daily dose of XEN1101 during this extension period.

03

Conditions studied

  • Focal Epilepsy

Keywords

  • Epilepsy
04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Be properly informed of the nature and risks of the study and give in writing, prior to entering the study
  • ≤40 kg/m2
  • Diagnosis (≥2 years) of focal epilepsy according to the International League Against Epilepsy [ILAE] Classification of Epilepsy (2017)
  • Prior neuroimaging within the last 10 years and documentation is available
  • Treatment with a stable dose of 1 to 3 allowable current AEDs for at least one month prior to screening, during baseline, and throughout the duration of the DBP
  • Must be willing to comply with the requirements
  • Males must agree not to donate sperm from the time of the first administration of study drug until 3 months after the last dose. Females must agree not to donate ova from the time of the first administration of study drug until 3 months after the last dose.
  • Able to keep accurate seizure diaries

Key Exclusion Criteria:

  • History of pseudoseizures, psychogenic seizures, primary generalized seizure, or focal aware non-motor seizures only
  • Presence or previous history of Lennox-Gastaut syndrome
  • Seizures secondary to other diseases or conditions
  • History of repetitive seizures within the last 12 months where the individual seizures cannot be counted
  • History of neurosurgery for seizures \<1 year prior to enrollment, or radiosurgery \<2 years prior to enrollment
  • Schizophrenia and other psychotic disorders, or active suicidal plan/intent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt
  • History or presence of any significant medical or surgical condition or uncontrolled medical illness at screening, or history of cancer within the past 2 years, with the exception of appropriately treated basal cell or squamous cell carcinoma
  • Any abnormalities on pre-study physical examination, vital signs, laboratory values or indicating a medical problem that would preclude study participation including but not limited to:

    1. History of presence of long syndrome; QTcF > 450 msec at baseline; family history of sudden death of unknown cause
    2. History of skin or retinal pigment epithelium abnormalities caused by ezogabine
  • Past use of vigabatrin without stable visual fields tested twice over the 12 months after the last dose of vigabatrin (concomitant use of vigabatrin is not allowed)
  • If felbamate is used as a concomitant AED, patients must be taking it for at least 2 years, with a stable dose for 2 months (or no less than 49 days) and acceptable hematology and LFT history and values prior to Screening. If received in the past, felbamate must have been discontinued 2 months (or no less than 49 days) prior to Screening.
  • Have had multiple drug allergies or a severe drug reaction to an AED(s), including dermatological (e.g., Stevens-Johnson syndrome), hematological, or organ toxicity reactions
  • Current use of a ketogenic diet
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
325 participants (actual)

Study arms

  • Experimental
    25 mg XEN1101

    Capsule filled with 25 mg XEN1101

    Drug: XEN1101

  • Experimental
    20 mg XEN1101

    Capsule filled with 20 mg XEN1101

    Drug: XEN1101

  • Experimental
    10 mg XEN1101

    Capsule filled with 10 mg XEN1101

    Drug: XEN1101

  • Placebo comparator
    Placebo

    Placebo capsule

    Drug: XEN1101

Interventions

06

What researchers measure

Primary outcomes

  1. Median Percent Change in Focal Seizure Frequency

    Median percent change in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo

    Time frame: From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)

Secondary outcomes

  1. 50% XEN1101 Response Rate

    Responders are defined as patients experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline to DBP

    Time frame: From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)

  2. Percent Change in Focal Seizure Frequency Over Time

    Percent change from baseline in focal seizure frequency at Month 1 and Month 2 in the DBP

    Time frame: From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)

07

Results

Posted Sep 24, 2024

Participant flow

Participant flow — Overall Study
Milestone25 mg XEN110120 mg XEN110110 mg XEN1101Placebo
Started1145146114
Completed884345109
Not completed26815

Outcome measures

PrimaryMedian Percent Change in Focal Seizure Frequency

Median percent change in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo

Time frame:
From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)
Reported as:
Median · Percent change
Median Percent Change in Focal Seizure Frequency
Percent change25 mg XEN110120 mg XEN110110 mg XEN1101Placebo
Median Percent Change in Focal Seizure Frequency-52.8 (-80.4 to -16.9)-46.4 (-76.7 to -14.0)-33.2 (-61.8 to 0.0)-18.2 (-37.3 to 7.0)
Secondary50% XEN1101 Response Rate

Responders are defined as patients experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline to DBP

Time frame:
From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)
Reported as:
Count of participants · Participants
50% XEN1101 Response Rate
Participants25 mg XEN110120 mg XEN110110 mg XEN1101Placebo
50% XEN1101 Response Rate61221317
SecondaryPercent Change in Focal Seizure Frequency Over Time

Percent change from baseline in focal seizure frequency at Month 1 and Month 2 in the DBP

Time frame:
From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)
Reported as:
Median · Percent change from baseline
Percent Change in Focal Seizure Frequency Over Time
Percent change from baseline25 mg XEN110120 mg XEN110110 mg XEN1101Placebo
Month 1 (Day 1 to 28)-55.3 (-78.3 to -16.1)-40.0 (-70.7 to -1.3)-40.1 (-62.5 to -1.5)-14.9 (-38.6 to 15.9)
Month 2 (Day 29 to Visit 8)-64.7 (-91.1 to -32.8)-52.2 (-81.1 to -33.7)-30.3 (-56.9 to 0.3)-21.8 (-45.6 to 4.9)

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
25 mg XEN11010/114 (0%)3/114 (2.6%)97/114 (85.1%)
20 mg XEN11010/51 (0%)2/51 (3.9%)35/51 (68.6%)
10 mg XEN11010/46 (0%)2/46 (4.3%)31/46 (67.4%)
Placebo0/114 (0%)3/114 (2.6%)56/114 (49.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
Event25 mg XEN110120 mg XEN110110 mg XEN1101Placebo
Confusional statePsychiatric disorders0/1140/511/460/114
SeizureNervous system disorders0/1140/511/460/114
HyponatremiaMetabolism and nutrition disorders0/1140/511/460/114
Psychotic disorderPsychiatric disorders0/1141/510/460/114
Somatic delusionPsychiatric disorders0/1141/510/460/114
Psychogenic seizurePsychiatric disorders1/1140/510/460/114
DizzinessNervous system disorders1/1140/510/460/114
Muscle spasticityNervous system disorders1/1140/510/460/114
Partial seizuresNervous system disorders0/1140/510/461/114
PresyncopeNervous system disorders0/1140/510/461/114
Most frequent other events
Showing 10 of 19
Most frequent other events
Event25 mg XEN110120 mg XEN110110 mg XEN1101Placebo
DizzinessNervous system disorders36/11413/513/468/114
SomnolenceNervous system disorders17/11411/515/468/114
HeadacheNervous system disorders9/1146/516/469/114
FatigueGeneral disorders14/1144/515/466/114
Balance disorderNervous system disorders13/1144/512/462/114
TremorNervous system disorders12/1143/513/462/114
AnxietyPsychiatric disorders2/1145/510/466/114
Urinary tract infectionInfections and infestations2/1143/514/464/114
AphasiaNervous system disorders8/1141/511/461/114
DysarthriaNervous system disorders8/1140/511/460/114

Baseline characteristics

Age, Customized
Age, Customized(years)25 mg XEN110120 mg XEN110110 mg XEN1101PlaceboTotal
Age38.7 ± 13.141.7 ± 13.640.0 ± 12.142.9 ± 13.740.8 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)25 mg XEN110120 mg XEN110110 mg XEN1101PlaceboTotal
Female54262761168
Male60251953157
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)25 mg XEN110120 mg XEN110110 mg XEN1101PlaceboTotal
Asian10124
Black or African American212712
Native Hawaiian or Other11013
White or Caucasian1054942102298
Other50128
Monthly seizure frequency in baseline
Monthly seizure frequency in baseline(seizures/month (28 days))25 mg XEN110120 mg XEN110110 mg XEN1101PlaceboTotal
Median12.8 (8.4 to 24.6)14.5 (7.5 to 36.4)17.4 (8.0 to 55.6)13.4 (8.0 to 30.1)13.5 (7.9 to 30.3)
08

Study locations

95 sites
09

References and documents

Publications

  • French JA, Porter RJ, Perucca E, Brodie MJ, Rogawski MA, Pimstone S, Aycardi E, Harden C, Qian J, Rosenblut CL, Kenney C, Beatch GN; X-TOLE Study Group. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial. JAMA Neurol. 2023 Nov 1;80(11):1145-1154. doi: 10.1001/jamaneurol.2023.3542. PubMed 37812429 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2019 to primary completion in Sep 2021, 31 months.

Results were first posted in Sep 2024, 3 years after primary completion. A results delay was requested in Aug 2022.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2028 → Oct 2030, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2019
First posted
Jan 8, 2019
StartActual
Jan 30, 2019
Primary completionActual
Sep 2, 2021
CompletionEst.
Oct 2030was Oct 2028
Results delay requested
Aug 18, 2022
Results first posted
Sep 24, 2024
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
27 sites added, 27 sites removed
Show 27 added (14 Spain, 7 Italy, 2 Germany, 2 United Kingdom, 1 United States, 1 Ukraine)
  • Boston Neuro Research Center · Russells Mills, United States
  • Universitatsklinikum Freiburg, Neurozentrum/Epilepsiezentrum · Freiburg im Breisgau, Germany
  • University Hospital Munster (UKM) · Münster, Germany
  • IRCCS- Istituto delle Scienze Neurologiche, Bellaria Hospital · Bologna, Italy
  • Dipartimento Scienze Mediche e Chirurgiche, Universita Magna Graecia di Catanzaro · Catanzaro, Italy
  • Fondazione IRCCS Istituto Neurologico C. Besta · Milan, Italy
  • IRCCS Istituto Neurologico Nazionale C. Mondino · Pavia, Italy
  • Azienda Ospedaliera Universita' Pisana · Pisa, Italy
  • Azienda Ospedaliera "Bianchi-Melacrino-Morelle"di Reggio Calabria · Reggio Calabria, Italy
  • Policlinico di Roma Umberto I · Roma, Italy
  • Hospital Virgen Macarena · Seville, Spain
  • Centro de Neurologia Avanzada · Seville, Spain
  • Hospital del Mar · Barcelona, Spain
  • Hospital Universitario Vall d'Hebron · Barcelona, Spain
  • Hospital Vithas La Salud · Granada, Spain
  • Hospital U. Ramón y Cajal · Madrid, Spain
  • Hospital Ruber Internacional · Madrid, Spain
  • Hospital U. Clínico San Carlos · Madrid, Spain
  • Hospital Universitario Fundacion Jimenez Diaz · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Regional Universitario de Málaga · Málaga, Spain
  • Clínica Universidad Navarra · Pamplona, Spain
  • Hospital Universitario y Politécnico La Fe · Valencia, Spain
  • Hospital Clínico Universitario Valladolid · Valladolid, Spain
  • Medical Center of Limited Liability Company "Harmoniya Krasy" · Kyiv, Ukraine
  • King's College Hospital NHS Foundation Trust · London, United Kingdom
  • St. George's University Hospitals NHS Foundation Trust · London, United Kingdom
Show 27 removed
  • Boston Neuro Research Center · South Dartmouth, United States
  • Universitatsklinikum Freiburg, Neurozentrum/Epilepsiezentrum · Freiburg, Germany
  • University Hospital Munster (UKM) · Muenster, Germany
  • IRCCS- Istituto delle Scienze Neurologiche, Bellaria Hospital · Bologna, Italy
  • Dipartimento Scienze Mediche e Chirurgiche, Universita Magna Graecia di Catanzaro · Catanzaro, Italy
  • Fondazione IRCCS Istituto Neurologico C. Besta · Milano, Italy
  • IRCCS Istituto Neurologico Nazionale C. Mondino · Pavia, Italy
  • Azienda Ospedaliera Universita' Pisana · Pisa, Italy
  • Azienda Ospedaliera "Bianchi-Melacrino-Morelle"di Reggio Calabria · Reggio Calabria, Italy
  • Policlinico di Roma Umberto I · Roma, Italy
  • Hospital Virgen Macarena · Sevilla, Spain
  • Centro de Neurologia Avanzada · Sevilla, Spain
  • Clínica Universidad Navarra · Pamplona, Spain
  • Hospital del Mar · Barcelona, Spain
  • Hospital Universitario Vall d'Hebron · Barcelona, Spain
  • Hospital Vithas La Salud · Granada, Spain
  • Hospital U. Ramón y Cajal · Madrid, Spain
  • Hospital Ruber Internacional · Madrid, Spain
  • Hospital U. Clínico San Carlos · Madrid, Spain
  • Hospital Universitario Fundacion Jimenez Diaz · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Regional Universitario de Málaga · Málaga, Spain
  • Hospital Universitario y Politécnico La Fe · Valencia, Spain
  • Hospital Clínico Universitario Valladolid · Valladolid, Spain
  • Medical Center of Limited Liability Company "Harmoniya Krasy" · Kyiv, Ukraine
  • King's College Hospital NHS Foundation Trust · London, United Kingdom
  • St. George's University Hospitals NHS Foundation Trust · London, United Kingdom
Nov 5, 2026
Study completion
Oct 2028→Oct 2030
Nov 5, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedMales must agree not to donate sperm from the time of the first administration of study drug until 63 months after the last dose. Females must agree not to donate ova from the time of the first administration of study drug until 63 months after the last dose.
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    27 sites added, 27 sites removed
    Show 27 added (14 Spain, 7 Italy, 2 Germany, 2 United Kingdom, 1 United States, 1 Ukraine)
    • Boston Neuro Research Center · Russells Mills, United States
    • Universitatsklinikum Freiburg, Neurozentrum/Epilepsiezentrum · Freiburg im Breisgau, Germany
    • University Hospital Munster (UKM) · Münster, Germany
    • IRCCS- Istituto delle Scienze Neurologiche, Bellaria Hospital · Bologna, Italy
    • Dipartimento Scienze Mediche e Chirurgiche, Universita Magna Graecia di Catanzaro · Catanzaro, Italy
    • Fondazione IRCCS Istituto Neurologico C. Besta · Milan, Italy
    • IRCCS Istituto Neurologico Nazionale C. Mondino · Pavia, Italy
    • Azienda Ospedaliera Universita' Pisana · Pisa, Italy
    • Azienda Ospedaliera "Bianchi-Melacrino-Morelle"di Reggio Calabria · Reggio Calabria, Italy
    • Policlinico di Roma Umberto I · Roma, Italy
    • Hospital Virgen Macarena · Seville, Spain
    • Centro de Neurologia Avanzada · Seville, Spain
    • Hospital del Mar · Barcelona, Spain
    • Hospital Universitario Vall d'Hebron · Barcelona, Spain
    • Hospital Vithas La Salud · Granada, Spain
    • Hospital U. Ramón y Cajal · Madrid, Spain
    • Hospital Ruber Internacional · Madrid, Spain
    • Hospital U. Clínico San Carlos · Madrid, Spain
    • Hospital Universitario Fundacion Jimenez Diaz · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Regional Universitario de Málaga · Málaga, Spain
    • Clínica Universidad Navarra · Pamplona, Spain
    • Hospital Universitario y Politécnico La Fe · Valencia, Spain
    • Hospital Clínico Universitario Valladolid · Valladolid, Spain
    • Medical Center of Limited Liability Company "Harmoniya Krasy" · Kyiv, Ukraine
    • King's College Hospital NHS Foundation Trust · London, United Kingdom
    • St. George's University Hospitals NHS Foundation Trust · London, United Kingdom
    Show 27 removed
    • Boston Neuro Research Center · South Dartmouth, United States
    • Universitatsklinikum Freiburg, Neurozentrum/Epilepsiezentrum · Freiburg, Germany
    • University Hospital Munster (UKM) · Muenster, Germany
    • IRCCS- Istituto delle Scienze Neurologiche, Bellaria Hospital · Bologna, Italy
    • Dipartimento Scienze Mediche e Chirurgiche, Universita Magna Graecia di Catanzaro · Catanzaro, Italy
    • Fondazione IRCCS Istituto Neurologico C. Besta · Milano, Italy
    • IRCCS Istituto Neurologico Nazionale C. Mondino · Pavia, Italy
    • Azienda Ospedaliera Universita' Pisana · Pisa, Italy
    • Azienda Ospedaliera "Bianchi-Melacrino-Morelle"di Reggio Calabria · Reggio Calabria, Italy
    • Policlinico di Roma Umberto I · Roma, Italy
    • Hospital Virgen Macarena · Sevilla, Spain
    • Centro de Neurologia Avanzada · Sevilla, Spain
    • Clínica Universidad Navarra · Pamplona, Spain
    • Hospital del Mar · Barcelona, Spain
    • Hospital Universitario Vall d'Hebron · Barcelona, Spain
    • Hospital Vithas La Salud · Granada, Spain
    • Hospital U. Ramón y Cajal · Madrid, Spain
    • Hospital Ruber Internacional · Madrid, Spain
    • Hospital U. Clínico San Carlos · Madrid, Spain
    • Hospital Universitario Fundacion Jimenez Diaz · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Regional Universitario de Málaga · Málaga, Spain
    • Hospital Universitario y Politécnico La Fe · Valencia, Spain
    • Hospital Clínico Universitario Valladolid · Valladolid, Spain
    • Medical Center of Limited Liability Company "Harmoniya Krasy" · Kyiv, Ukraine
    • King's College Hospital NHS Foundation Trust · London, United Kingdom
    • St. George's University Hospitals NHS Foundation Trust · London, United Kingdom
    Study completion Oct 2028→Oct 2030
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedMales must agree not to donate sperm from the time of the first administration of study drug until 63 months after the last dose. Females must agree not to donate ova from the time of the first administration of study drug until 63 months after the last dose.
    + 4 other changes: identifiers, verification date, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03796962
Collaborators
Novotech Health Holdings Pte. Ltd.
Responsible party
Sponsor
First posted
Jan 8, 2019
Start date
Jan 30, 2019
Primary completion
Sep 2, 2021
Completion
Oct 2030 (estimated)
Results posted
Sep 24, 2024
Last update
Nov 5, 2026

Study contacts

Study Director
study director · Xenon Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XEN1101

Start the discussion